Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11377449 BTK inhibitors with improved dual selectivity

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

July 5, 2022

Patent Application Number

16637615

Date Filed

August 12, 2018

Patent Citations

US Patent 10927117 Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

US Patent 10005782 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators

US Patent 10570139 Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators

Patent Citations Received

US Patent 11512132 Anti-PD-L1 antibodies and their use as therapeutics and diagnostics

US Patent 11701357 Treatment of B cell cancers using a combination comprising Btk inhibitors

0

US Patent 11786529 Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors

Patent Primary Examiner

CPC Code

Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11377449 BTK inhibitors with improved dual selectivity

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool